Akagera Medicines Secures $7.8 Million Grant for TB Vaccine Development Initiative

Akagera Medicines Secures $7.8 Million Grant for TB Vaccine Development



Akagera Medicines, Inc., a biopharmaceutical company focused on innovative therapies for infectious diseases, has been awarded a substantial $7.8 million grant from the Gates Foundation to advance its dendritic cell-targeted mRNA vaccine for tuberculosis (TB). As a clinical-stage entity, Akagera aims to transform TB vaccine research with novel approaches utilizing lipid nanoparticle (LNP) technology, designed to specifically target dendritic cells and elicit robust immune responses.

The recent funding expands the total commitment under the grant to $9.79 million, which will be used to support the Good Manufacturing Practice (GMP) manufacturing processes and critical toxicology studies needed for filing an Investigational New Drug (IND) application. This funding marks an important transition for Akagera, moving their vaccine from preclinical feasibility to clinical development, with plans for a first-in-human Phase 1 trial.

The Urgency of a New TB Vaccine



Despite being preventable and treatable, tuberculosis remains one of the deadliest infectious diseases globally, claiming over a million lives every year. The existing BCG vaccine has limitations, particularly for adolescents and adults, who are primarily responsible for TB transmission. There is a pressing need for an effective vaccine that provides comprehensive protection to these vulnerable populations.

Akagera's innovative approach combines mRNA technology with LNPs to deliver Mycobacterium tuberculosis antigens directly to dendritic cells. These cells play a crucial role in the immune system by presenting antigens and activating T-cells, which are essential for a strong immune response against TB. This targeted delivery aims not only to improve the immunogenicity of the vaccine but also to reduce the required dosage and enhance tolerability among recipients.

Progress and Future Plans



In 2023, Akagera initiated its research with initial funding from the Gates Foundation, demonstrating promising results in preclinical studies. These studies indicated a strong immunogenic response using an mRNA vaccine candidate encoding nine distinct TB antigens, notably activating human peripheral blood immune cells. With this new grant, Akagera is set to enhance the development process through:
  • - Process Development and GMP Manufacturing: Preparing clinical trial materials in accordance with regulatory standards.
  • - IND-Enabling Toxicology Studies: Conducting safety assessments to ensure the vaccine's viability for human trials.
  • - Regulatory Preparation: Compiling a comprehensive regulatory package to support the future IND filing and upcoming clinical trials.

Quotes from Leadership



Daryl Drummond, Ph.D., Co-Founder and Chief Scientific Officer of Akagera Medicines, emphasized, "This expanded support from the Gates Foundation marks the transition of our TB vaccine program from proof of concept to clinical readiness. Targeting mRNA delivery to dendritic cells lets us focus on the immune response where it matters most for TB."

Additionally, Michael Fairbanks, Co-Founder and Executive Chairman, stated, "Tuberculosis falls hardest on communities with limited access to new medicines. The Gates Foundation's continued funding allows us to advance a vaccine designed from the start for those who need it most, alongside our long-acting TB therapeutic, AKG-100."

About Akagera Medicines



Based in Waltham, Massachusetts, Akagera Medicines, Inc. is dedicated to developing lipid nanoparticle formulations aimed at combating tuberculosis and other infectious diseases like RSV, influenza, Lassa fever, and HIV. Their lead therapeutic, AKG-100—a long-acting intravenous treatment for both drug-susceptible and drug-resistant TB—reported favorable results in first-in-human single-ascending-dose data in 2026.

The company operates a subsidiary in Kigali, Rwanda, emphasizing their commitment to addressing health challenges faced in low- and middle-income countries, aiming to ensure that vital medical advancements benefit those in need most effectively.

In conclusion, Akagera Medicines’ impressive funding success represents a crucial step forward in the battle against tuberculosis, highlighting the significance of innovative research partnerships in tackling global health challenges. More information can be found on their official website: www.akageramedicines.com.

Topics Health)

【About Using Articles】

You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.

【About Links】

Links are free to use.